Data from the EULAR COVAX physician-reported registry indicate that disease flares and serious adverse events rarely occur after SARS-CoV-2 vaccination in adolescents with inflammatory rheumatic and musculoskeletal diseases (RMD) and adults with juvenile idiopathic arthritis (JIA). RMD flare occurred in 1 of the 36 adolescents and 2 of the 74 adults in the dataset; only one serious adverse event was reported, in the adolescent group. Mild to moderate adverse events were common, but their frequency and profile was similar to that seen in the general population.
References
Original article
Lawson-Tovey, S. et al. SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry. RMD Open 8, e002322 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Onuora, S. SARS-CoV-2 vaccine safe for young patients. Nat Rev Rheumatol 18, 552 (2022). https://doi.org/10.1038/s41584-022-00831-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-022-00831-2